HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Challenges Sustainability Buffs To Develop Packaging Alternatives

Executive Summary

As part of its mission to make 100% of its consumer health packaging recyclable or reusable by 2030, Bayer is seeking partners to develop sustainable alternatives for its products.

You may also be interested in...



GSCF World Congress: Environmental Sustainability In Consumer Health

The third session on day one of the GSCF's World Congress 2022 focused on sustainability and featured contributions from Haleon, Bayer, AESGP, and the UN.

Haleon, Teva And PAGB Join UK Sustainable Medicines Partnership

Haleon, Teva and UK consumer healthcare industry association, PAGB, are among 42 members of the Sustainable Medicines Partnership, which “aims to build science-based, scalable, sustainable solutions to help reduce the waste of medicines and the waste from medicines.”

AESGP Annual Meeting, Day 2 (Part 3): Reckitt Calls For AESGP Sustainability Consortium

At the third session of the AESGP 58th Annual Meeting in Madrid, Spain, Reckitt's head of product sustainability and stewardship Oliver Price called on the association to explore consortia relating to shared sustainability issues within the Europe's consumer healthcare sector. Also in the session, regulatory experts Andrew Fasey, Mayer Brown Europe, and Sevrine Peraira, Europen, critically examined major pieces of incoming legislation related to the EU Green Deal, pointing to areas of concern for the OTC industry. 

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS153019

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel